Evidence map›Paper›PMID 23193181›Full record

Trial reportDiabetes2013

High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition.

Morten M Poulsen, Poul F Vestergaard, Berthil F Clasen, Yulia Radko, Lars P Christensen, Hans Stødkilde-Jørgensen, Niels Møller, Niels Jessen, Steen B Pedersen, Jens Otto L Jørgensen

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 222 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
222citing papers in PubMed, 13 pooled it
24.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

222 citing papers in PubMed, 13 syntheses or guidelines pooled it, 438 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Resveratrol Improves Vascular Function and Mitochondrial Number but Not Glucose Metabolism in Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2017
    Trial
  19. Trial
  20. Trial

162 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Morten M PoulsenDepartment of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark. mmp@ki.au.dk
Poul F Vestergaard
Berthil F Clasen
Yulia Radko
Lars P Christensen
Hans Stødkilde-Jørgensen
Niels Møller
Niels Jessen
Steen B Pedersen
Jens Otto L Jørgensen
Aarhus University Hospital · DKUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity, diabetes, hypertension, and hyperlipidemia constitute risk factors for morbidity and premature mortality. Based on animal and in vitro studies, resveratrol reverts these risk factors via stimulation of silent mating type information regulation 2 homolog 1 (SIRT1), but data in human subjects are scarce. The objective of this study was to examine the metabolic effects of high-dose resveratrol in obese human subjects. In a randomized, placebo-controlled, double-blinded, and parallel-group design, 24 obese but otherwise healthy men were randomly assigned to 4 weeks of resveratrol or placebo treatment. Extensive metabolic examinations including assessment of glucose turnover and insulin sensitivity (hyperinsulinemic euglycemic clamp) were performed before and after the treatment. Insulin sensitivity, the primary outcome measure, deteriorated insignificantly in both groups. Endogenous glucose production and the turnover and oxidation rates of glucose remained unchanged. Resveratrol supplementation also had no effect on blood pressure; resting energy expenditure; oxidation rates of lipid; ectopic or visceral fat content; or inflammatory and metabolic biomarkers. The lack of effect disagrees with persuasive data obtained from rodent models and raises doubt about the justification of resveratrol as a human nutritional supplement in metabolic disorders.

Indexed as

AdolescentAdultAgedAntioxidantsBody CompositionDietary SupplementsDose-Response Relationship, DrugDouble-Blind MethodEnergy MetabolismGene Expression RegulationHumansInsulin ResistanceMaleMiddle AgedObesityPilot ProjectsAntioxidantsResveratrolStilbenes

Identifiers

PMID23193181
PMCPMC3609591
OpenAlexW2144770293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.